TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10744931

Group type: EXPERIMENTAL
Intervention: Low pressure suction drainage (Exudrain)
Number of subjects: 69

Group type: COMPARATOR
Intervention: High pressure suction drainage (Redivac)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study: 8862936

Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg i.v. on day 1 followed by 7 days oral treatment with one 15 mg tablet daily
Number of subjects: 183

Group type: COMPARATOR
Intervention: Diclofenac 75 mg i.m. on day 1 followed by 7 days treatment with one 100 mg slow release tablet daily
Number of subjects: 183
Study: 1442760

Group type: EXPERIMENTAL
Intervention: Lidocaine gel patch (10% lidocaine base with 3% glycyrrhetinic acid) applied for 60 minutes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo gel patch (without lidocaine)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lidocaine gel patch
Number of subjects: 16
Study: 3899624

Group type: EXPERIMENTAL
Intervention: Flunarizine at doses of 0, 10, 15, 20, and 25 mg daily
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Flunarizine at doses of 15-20 mg daily
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 47
Study: 30587335

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hospitalization or intravenous antibiotics
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Post-PEx recovery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Physical Functioning and Vitality
Number of subjects: 80
Study: 28657111

Group type: EXPERIMENTAL
Intervention: Systemic couple therapy (5 sessions)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: EVOS scale
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: EVOS in Study 2
Number of subjects: 43
Study: 25991692

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate 500 mg, three times daily for 12 weeks
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 23612890

Group type: EXPERIMENTAL
Intervention: Culturally appropriate intervention for oral health self-care practices
Number of subjects: 284
Study: 22432232

Group type: EXPERIMENTAL
Intervention: Straw usage for 2 days after surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: No straw usage for 2 days after surgery
Number of subjects: 60
Study: 20051836

Group type: EXPERIMENTAL
Intervention: Tinzaparin (2,000 U per catheter line)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) (5,000 U per catheter line)
Number of subjects: 42
Study: 17913003

Group type: EXPERIMENTAL
Intervention: Crest Whitestrips bleaching gels (5.3% and 6.5% hydrogen peroxide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo gels (no hydrogen peroxide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study: 16220234

Group type: EXPERIMENTAL
Intervention: Character education program (school-based and curriculum driven)
Number of subjects: 303

Group type: COMPARATOR
Intervention: No treatment control condition
Number of subjects: 303
Study: 11872367

Group type: EXPERIMENTAL
Intervention: Troglitazone group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 10193952

Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2 on Day 1) and Etoposide (100 mg/m2 on Days 1, 3, and 5 or Days 4, 6, and 8 every 3 weeks)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Cisplatin and Etoposide
Number of subjects: 107
Study: 7852684

Group type: EXPERIMENTAL
Intervention: Vegetarians
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lactovegetarians
Number of subjects: 45
Study: 2322495

Group type: EXPERIMENTAL
Intervention: High nickel diet (supplementary for 4 days)
Number of subjects: 12
Study: 229146

Group type: EXPERIMENTAL
Intervention: Flurazepam hydrochloride (15 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30980771

Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation procedure using collagenated bovine bone mineral and a resorbable collagen membrane
Number of subjects: 40

Group type: COMPARATOR
Intervention: No grafting (control)
Number of subjects: 40
Study: 28706955

Group type: EXPERIMENTAL
Intervention: Breakfast B1 (milk and cereals)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Breakfast B2 (milk, apple, and chocolate cream‐filled sponge cake)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Breakfast B3 (milk, apple, bread, and hazelnut chocolate cream)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All breakfasts (B1, B2, B3)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control A (50 g OGTT)
Number of subjects: 12
Study: 25861028

Group type: EXPERIMENTAL
Intervention: Sine wave tracking (45 trials)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typical Fitts task (ID = 6) (45 trials)
Number of subjects: 0
Study: 23984352

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy plus EMT with a resistive load of 30 cm H2O
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chest physiotherapy plus EMT with a sham load
Number of subjects: 60
Study: 20189663

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (11 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 37
Study: 19468716

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 16505423

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 77
Study: 14764220

Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous veno-venous hemofiltration (CVVH)
Number of subjects: 12
Study: 11243489

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.3 mg/70 kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.6 mg/70 kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9302888

Group type: EXPERIMENTAL
Intervention: Audio guidance system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper map
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head-up turn-by-turn display
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head-down electronic map
Number of subjects: 0

Group type: COMPARATOR
Intervention: Head-down turn-by-turn display
Number of subjects: 0
Study: 8111818

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Flunisolide with menthol
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Flunisolide
Number of subjects: 102

Group type: COMPARATOR
Intervention: Flunisolide without menthol
Number of subjects: 102
Study: 3488532

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (600 mg, five times a day for ten days)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 31781605

Group type: EXPERIMENTAL
Intervention: Knowledge about diabetes
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Risk perception for developing diabetes
Number of subjects: 527

Group type: COMPARATOR
Intervention: Education level
Number of subjects: 527
Study: 30037498

Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemo-radiotherapy (CCRT)
Number of subjects: 1633

Group type: COMPARATOR
Intervention: Chemotherapy alone (CA)
Number of subjects: 1633
Study: 27504605

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 714

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 714
Study: 25310116

Group type: EXPERIMENTAL
Intervention: Clinic-based peer support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based peer support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 22459311

Group type: EXPERIMENTAL
Intervention: High dairy intake (four serves/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Low dairy intake (one serve/day)
Number of subjects: 38
Study: 19422657

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 26
Study: 18343277

Group type: EXPERIMENTAL
Intervention: Certo-lizumab pegol
Number of subjects: 662
Study: 15842271

Group type: EXPERIMENTAL
Intervention: Sonic scaler
Number of subjects: 74

Group type: COMPARATOR
Intervention: Piezoceramic ultrasonic scaler
Number of subjects: 74
Study: 12452227

Group type: EXPERIMENTAL
Intervention: 20 ml of 0.5 per cent bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study: 10077358

Group type: EXPERIMENTAL
Intervention: Low dose Testosterone TTS type 1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High dose Testosterone TTS type 1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low dose Testosterone TTS type 2
Number of subjects: 6

Group type: COMPARATOR
Intervention: GnRH antagonist (cetrorelix)
Number of subjects: 6
Study: 7559090

Group type: EXPERIMENTAL
Intervention: Dietary guidance alone (Regimen I)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dietary guidance plus eating wheat bran biscuits (Regimen II)
Number of subjects: 200
Study: 2149492

Group type: EXPERIMENTAL
Intervention: Teicoplanin (6 mg/kg every 24 h intravenously)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vancomycin (15 mg/kg every 12 h intravenously)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 50
Study: 6112931

Group type: EXPERIMENTAL
Intervention: KWD 2131 (5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Terbutaline (5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DSCG (40 mg)
Number of subjects: 10
Study: 31168938

Group type: EXPERIMENTAL
Intervention: BP + DU therapy
Number of subjects: 54
Study: 30455246

Group type: EXPERIMENTAL
Intervention: 10‐mg/kg of body weight bezlotoxumab
Number of subjects: 1587
Study: 27282077

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Current Usual Practice Approach (CUPA)
Number of subjects: 18
Study: 25429550

Group type: EXPERIMENTAL
Intervention: Aerobic training for 6 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Resistance training for 6 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mixed training for 6 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All training groups (aerobic, resistance, mixed)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pre-training values
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CPC values 3 weeks after training
Number of subjects: 43
Study: 23328954

Group type: EXPERIMENTAL
Intervention: Imatinib therapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dasatinib therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Initial LSC percentage
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison of LSCs and LPCs at diagnosis
Number of subjects: 46
Study: 21159328

Group type: EXPERIMENTAL
Intervention: Group-based cognitive behavioral intervention
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Individually based virtual reality exposure
Number of subjects: 91
Study: 20076861

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400mg administered orally 60 minutes before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo administered orally 60 minutes before surgery
Number of subjects: 60
Study: 17630037

Group type: COMPARATOR
Intervention: Single-agent fluorouracil (with levofolinate over 48 h every 2 weeks) until failure, then single-agent irinotecan (Control group A)
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Fluorouracil until failure, then combination chemotherapy (Strategy B)
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy from the outset (Strategy C)
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Combination strategy including irinotecan (C-ir)
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Overall comparison of strategy B with strategy C
Number of subjects: 2135
Study: 15001463

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (15 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Noncaffeinated coffee (15 g) (control)
Number of subjects: 20
Study: 11157320

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (0.9% Ca by wt, 0.9 g Ca/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control diet (without calcium supplementation)
Number of subjects: 10
Study: 9621290

Group type: EXPERIMENTAL
Intervention: Nephrotic patients
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 8
Study: 7918290

Group type: EXPERIMENTAL
Intervention: Oral albendazole 15 mg/kg once daily for 1 month
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3049266

Group type: EXPERIMENTAL
Intervention: Terguride 0.5 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Terguride 1.0 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Terguride 0.25 mg
Number of subjects: 3
Study: 29182895

Group type: EXPERIMENTAL
Intervention: Downhill running training (DRG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Level running training (LRG)
Number of subjects: 18
Study: 28036334

Group type: EXPERIMENTAL
Intervention: Dofetilide (selective hERG potassium channel blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dofetilide (alone) and in combination with lidocaine and mexiletine (late sodium current blockers)
Number of subjects: 0
Study: 24662130

Group type: EXPERIMENTAL
Intervention: Cisplatin-adriamycin-paclitaxel (TAP) neoadjuvant chemotherapy for 3 cycles
Number of subjects: 30
Study: 22375970

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 219

Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 219
Study: 20044749

Group type: EXPERIMENTAL
Intervention: Replacement per kilogram of lean body mass (LBM) (2.5 mcg/kg LBM per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Replacement per kilogram of body weight (1.6 mcg/kg body weight per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empirical replacement of thyroxine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Replacement based on LBM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed-dose regimens based on body weight
Number of subjects: 0
Study: 18557262

Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard nursery care
Number of subjects: 66
Study: 16398378

Group type: EXPERIMENTAL
Intervention: LMA Classic
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: LMA Unique
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: SoftSeal
Number of subjects: 3
Study: 12869973

Group type: EXPERIMENTAL
Intervention: Optibond Solo Plus
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Single Bond
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Excite
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prompt L Pop
Number of subjects: 36
Study: 10501340

Group type: EXPERIMENTAL
Intervention: 6-month supervised exercise renal rehabilitation program (group A) consisting of three weekly sessions of aerobic training
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Moderate exercise program at home (group B)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No training (group C, control)
Number of subjects: 38
Study: 8601248

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty with laser assistance
Number of subjects: 82

Group type: COMPARATOR
Intervention: Balloon angioplasty alone
Number of subjects: 82
Study: 2027146

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation of the P6 antiemetic point (Neiguan) using a battery-operated TENS machine (15 Hz) for 5 minutes every 2 hours.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Self-administration of Sea Bands every 2 hours.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Invasive acupuncture (not directly tested in this study).
Number of subjects: 100
Study: 7293943

Group type: EXPERIMENTAL
Intervention: Iron therapy
Number of subjects: 69
Study: 30782974

Group type: EXPERIMENTAL
Intervention: Novelty-facilitated extinction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard extinction
Number of subjects: 0
Study: 29903274

Group type: EXPERIMENTAL
Intervention: Nutrition intervention with eggs and milk (200 g school milk and 50 g halogen eggs per school day)
Number of subjects: 672

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 672
Study: 27087059

Group type: EXPERIMENTAL
Intervention: Tocilizumab (4 or 8 mg/kg IV) + methotrexate
Number of subjects: 1149

Group type: COMPARATOR
Intervention: Placebo + methotrexate
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Tocilizumab + methotrexate
Number of subjects: 1149
Study: 25144847

Group type: EXPERIMENTAL
Intervention: Subacromial pain catheter with ropivacaine (n=33)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intraoperative administration of a single dose of ropivacaine (n=33)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative pain therapy (n=34)
Number of subjects: 100
Study: 21930244

Group type: EXPERIMENTAL
Intervention: 5-month weight loss intervention
Number of subjects: 189

Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 189
Study: 18951540

Group type: EXPERIMENTAL
Intervention: Real rTMS (1,800 pulses; 1 Hz rate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham rTMS (placebo)
Number of subjects: 10
Study: 18368870

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronisation Therapy (CRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI) techniques
Number of subjects: 0
Study: 15120371

Group type: EXPERIMENTAL
Intervention: Intraperitoneal hyperthermic chemotherapy (IPHC) with mitomycin C
Number of subjects: 34

Group type: COMPARATOR
Intervention: Radical gastrectomy without extended nodal resection (Control)
Number of subjects: 34
Study: 12172218

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Angiotensin II (AT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Noradrenaline (NA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: L-NMMA (NO-synthase inhibitor)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Yohimbine (YO)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Combined pretreatment with L-NMMA and YO
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: BQ-123 (ETA-antagonist)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: BQ-788 (ETB-antagonist)
Number of subjects: 25
Study: 11477844

Group type: EXPERIMENTAL
Intervention: Yishen Shengxue tablet (YSSXT)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Renshen Guipi Pill (RSGPP)
Number of subjects: 142
Study: 7662344

Group type: EXPERIMENTAL
Intervention: Oral feeding started on the 7th postoperative day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Oral feeding started on the 14th postoperative day
Number of subjects: 35
Study: 2665180

Group type: EXPERIMENTAL
Intervention: Low-dose iron supplement containing heme iron and non-heme iron (18-20 mg iron per day) for six months
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Low-dose iron supplement containing non-heme iron (18-20 mg iron per day) for six months
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: All supplements (including heme and non-heme iron)
Number of subjects: 170
Study: 337984

Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentazocine 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pethidine 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meptazinol or Morphine (further pain relief)
Number of subjects: 0
Study: 30522750

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy plus antispasmodic medication
Number of subjects: 149

Group type: COMPARATOR
Intervention: Antispasmodic alone
Number of subjects: 149
Study: 27037996

Group type: EXPERIMENTAL
Intervention: 70 mL of concentrated nitrate-rich beetroot juice (BR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study: 26439430

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Treatment responders at week 26 follow-up
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 99
Study: 23786774

Group type: EXPERIMENTAL
Intervention: Prophylactic paracetamol (125 mg or 250 mg suppositories based on body weight) administered at vaccination and at 6-8 hour intervals thereafter
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Prophylactic paracetamol
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (no paracetamol)
Number of subjects: 301
Study: 22117715

Group type: EXPERIMENTAL
Intervention: Instrumentation with ProTaper Starter Kit (Dentsply/Maillefer) rotary system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual instrumentation using K files (Dentsply/Maillefer) by crown‐down technique, cervical preparation with Gates‐Glidden #1 and #2 burs, and final preparation with ProTaper F2 and F3 rotary files
Number of subjects: 20
Study: 19826133

Group type: EXPERIMENTAL
Intervention: Academic detailing intervention
Number of subjects: 264

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 264
Study: 17041859

Group type: EXPERIMENTAL
Intervention: 3-target arm (with enfuvirtide)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 2-target arm (without enfuvirtide)
Number of subjects: 22
Study: 15327448

Group type: EXPERIMENTAL
Intervention: 100 microg oral misoprostol every 6 h for 48 h
Number of subjects: 153

Group type: COMPARATOR
Intervention: 50 microg vaginal misoprostol every 6 h for 48 h
Number of subjects: 153

Group type: COMPARATOR
Intervention: 50 microg vaginal misoprostol
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 100 microg oral misoprostol
Number of subjects: 153